BCL2L1 and acute myeloid leukemia: In contrast to MCL-1 and BCL-2, we found that although BCL-xL was expressed at high levels, it did not represent a prevalent therapeutic target in AML, with only one sensitive cell line (KASUMI-1) identified here.